New insider activity at Apnimed, Inc. ( (APMD) ) has taken place on August 3, 2026.

Director Paul Sekhri of Apnimed, Inc. has significantly increased his stake in the company by purchasing 12,500 shares of its stock in a recent transaction. The total value of this investment amounts to $200,000, signaling a notable show of confidence in Apnimed’s future prospects from within its leadership.

Apnimed Inc. saw notable attention as its IPO was priced at $16.00 per share for 12M shares, with the deal upsized from 10M and set at the high end of the $14.00–$16.00 range. The increased deal size and top-range pricing suggest strong investor demand and confidence in Apnimed’s late-stage pipeline of novel oral therapies for sleep-related breathing disorders, driving recent trading interest.